CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
This Document Has Been Replaced By: Update on Recommendations for Use of Herpes Zoster Vaccine
Superseded
This Document Has Been Replaced By: Update on Recommendations for Use of Herpes Zoster Vaccine
Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years
-
November 11, 2011
-
Source: MMWR. Morbidity and mortality weekly report. 2011; 60(44):1528.
[PDF-1.32 MB]
Details:
-
Journal Article:Morbidity and Mortality Weekly Report (MMWR)
-
Description:Herpes zoster vaccine (Zostavax, Merck & Co., Inc.) was licensed and recommended in 2006 for prevention of herpes zoster among adults aged 60 years and older. In March 2011, the Food and Drug Administration (FDA) approved the use of Zostavax in adults aged 50 through 59 years. In June 2011, the Advisory Committee on Immunization Practices (ACIP) declined to recommend the vaccine for adults aged 50 through 59 years and reaffirmed its current recommendation that herpes zoster vaccine be routinely recommended for adults aged 60 years and older.
-
Subjects:
-
Source:
-
Series:
-
ISSN:0149-2195 (print);1545-861X (digital);
-
Pubmed ID:22071592
-
Document Type:
-
Name as Subject:
-
Place as Subject:
-
Pages in Document:1 pdf page
-
Volume:60
-
Issue:44
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
